Abiopharma

🔍 Schellhase David (Director)

Company: Okta, Inc. (OKTA)

Report Date: 2026-04-16

Detailed Transactions and Holdings:

• Acquired 2,612 shares of Class A Common Stock at $71.8594 per share (Direct)
  Date: 2026-04-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,612.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,100 shares of Class A Common Stock at $72.4648 per share (Direct)
  Date: 2026-04-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 3,712.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 15, 2026.
• F2: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $71.31 to $72.29 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F3: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $72.33 to $72.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.